» Articles » PMID: 25162309

Iodine Quantification to Distinguish Clear Cell from Papillary Renal Cell Carcinoma at Dual-energy Multidetector CT: a Multireader Diagnostic Performance Study

Overview
Journal Radiology
Specialty Radiology
Date 2014 Aug 28
PMID 25162309
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate whether dual-energy multidetector row computed tomographic (CT) imaging with iodine quantification is able to distinguish between clear cell and papillary renal cell carcinoma ( RCC renal cell carcinoma ) subtypes.

Materials And Methods: In this retrospective, HIPAA-compliant, institutional review board-approved study, 88 patients (57 men, 31 women) with diagnosis of either clear cell or papillary RCC renal cell carcinoma at pathologic analysis, who underwent contrast material-enhanced dual-energy nephrographic phase study between December 2007 and June 2013, were included. Five readers, blinded to pathologic diagnosis, independently evaluated all cases by determining the lesion iodine concentration on color-coded iodine maps. The receiving operating characteristic curve analysis was adopted to estimate the optimal threshold for discriminating between clear cell and papillary RCC renal cell carcinoma , and results were validated by using a leave-one-out cross-validation. Interobserver agreement was assessed by using an intraclass correlation coefficient. The correlation between tumor iodine concentration and tumor grade was investigated.

Results: A tumor iodine concentration of 0.9 mg/mL represented the optimal threshold to discriminate between clear cell and papillary RCC renal cell carcinoma , and it yielded the following: sensitivity, 98.2% (987 of 1005 [95% confidence interval: 97.7%, 98.7%]); specificity, 86.3% (272 of 315 [95% confidence interval: 85.0%, 87.7%]); positive predictive value, 95.8% (987 of 1030 [95% confidence interval: 95.0%, 96.6%]); negative predictive value, 93.7% (272 of 290 [95% confidence interval: 92.8%, 94.7%]); overall accuracy of 95.3% (1259 of 1320 [95% confidence interval: 94.6%, 96.2%]), with an area under the curve of 0.923 (95% confidence interval: 0.913, 0.933). An excellent agreement was found among the five readers in measured tumor iodine concentration (intraclass correlation coefficient, 0.9990 [95% confidence interval: 0. 9987, 0.9993). A significant correlation was found between tumor iodine concentration and tumor grade for both clear cell (τ = 0.85; P < .001) and papillary RCC renal cell carcinoma (τ = 0.53; P < .001).

Conclusion: Dual-energy multidetector CT with iodine quantification can be used to distinguish between clear cell and papillary RCC renal cell carcinoma , and it provides insights regarding the tumor grade.

Citing Articles

Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT.

Mingkwansook V, Wangprasertkul U, Tarathipmon W, Watcharakorn A F1000Res. 2025; 13:498.

PMID: 39830626 PMC: 11739862. DOI: 10.12688/f1000research.146149.2.


Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma.

Chen W, Lin G, Li X, Feng Y, Mao W, Kong C Eur Radiol. 2024; .

PMID: 39414655 DOI: 10.1007/s00330-024-11109-4.


Standardization of Dual-Energy CT Iodine Uptake of the Abdomen and Pelvis: Defining Reference Values in a Big Data Cohort.

Yel I, Booz C, DAngelo T, Koch V, Gruenewald L, Eichler K Diagnostics (Basel). 2024; 14(18).

PMID: 39335730 PMC: 11431114. DOI: 10.3390/diagnostics14182051.


Development and validation of a CT based radiomics nomogram for preoperative prediction of ISUP/WHO grading in renal clear cell carcinoma.

Liu X, Han X, Wang X, Xu K, Wang M, Zhang G Abdom Radiol (NY). 2024; 50(3):1228-1239.

PMID: 39311950 DOI: 10.1007/s00261-024-04576-2.


Material density dual-energy CT images: value added in early diagnosis of peritoneal carcinomatosis : Original research.

Pisuchpen N, Lennartz S, Parakh A, Kongboonvijit S, Srinivas Rao S, Pierce T Abdom Radiol (NY). 2024; 49(10):3496-3506.

PMID: 38916617 DOI: 10.1007/s00261-024-04451-0.